Skip to main content

Table 2 Comparison of sVEGFR-3 plasma levels at baseline and at the end of the first treatment cycle (day 28 of cycle 1) in RCC patients. Only readings that were in the assay detection range are included in this table.

From: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

 

Mean

Median

Range (pg/mL)

sVEGFR-3

   

Cycle 1, Day 1 (n = 62)

71145.2

70700.0

23300 – 129200

Cycle 1, Day 28 (n = 44)

39520.5

37100.0

21500 – 64600